Oric Pharmaceuticals, Inc. (ORIC) analyst actions
Rating and price-target actions on ORIC in the public-source dataset. Wires and filings carry few rating actions, so this list is sparse by nature — the hub's by-event-type table holds the measured analyst base rates. Back to the ORIC overview →
2 measured ORIC analyst action events.
| Date | Headline | Event | 5-min | To close |
|---|---|---|---|---|
| ORIC® Pharmaceuticals Announces Initiation of Himalayas-1 Phase 3 Trial in mCRPC Evaluating Rinzimetostat in Combination with NUBEQA® (Darolutamide), Supported by Clinical Collaboration with Bayer | Press release | +0.62% | +6.09% | |
| Bronstein, Gewirtz & Grossman, LLC Initiates an Investigation into Allegations Against ORIC Pharmaceuticals, Inc. (ORIC) And Encourages Shareholders to Reach Out | Press release | +0.05% | -2.50% |
Keep exploring
More ORIC: earnings → · SEC filings → · ORIC overview →